Summit Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Summit Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-3.3%
Buyback Yield
| Total Shareholder Yield | -3.3% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?
Nov 08
Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market
Oct 04Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
Sep 19Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)
Sep 09Summit Therapeutics May Have Further Upside From Here
Aug 03Summit Therapeutics Stock: Plunging Despite A Win?
May 31Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer
May 06Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress
Jan 30We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely
Dec 29Summit Therapeutics slips on plans to terminate study for lead candidate
Oct 04Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio
Aug 17Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M
Aug 11Summit to explore additional trial for its bacteria-induced colon infection drug
Jul 14Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation
Apr 29Summit Therapeutics - Disappointing Data But Not An Outright Failure
Dec 23Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator
Jun 22Summit Therapeutics to join Russell 3000 Index
Jun 08Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if SMMT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SMMT's dividend payments have been increasing.
Dividend Yield vs Market
| Summit Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (SMMT) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.3% |
| Industry Average (Biotechs) | 2.3% |
| Analyst forecast (SMMT) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate SMMT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SMMT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate SMMT's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SMMT has not reported any payouts.